366 17 Synthetic Biology in Immunotherapy and Stem Cell Therapy Engineering
13 Bovenberg, M.S.S., Degeling, M.H., and Tannous, B.A. (2013) Advances in stem
cell therapy against gliomas. Trends Mol. Med., 19 (5), 281–291.
14 Boulikas, T. and Vougiouka, M. (2004) Recent clinical trials using cisplatin,
carboplatin and their combination chemotherapy drugs (review). Oncol. Rep.,
11 (3), 559–595.
15 Chang, Z.L. and Chen, Y.Y. (2017) CARs: synthetic immunoreceptors for cancer
therapy and beyond. Trends Mol. Med., 23 (5), 430–450.
16 Deeks, S.G., Wagner, B., Anton, P.A. et al. (2002) A phase II randomized study of
HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia
on combination antiretroviral therapy. Mol. Ther., 5 (6), 788–797.
17 Fransson, M., Piras, E., Burman, J. et al. (2012) CAR/FoxP3-engineered T
regulatory cells target the CNS and suppress EAE upon intranasal delivery.
J. Neuroinflammation, 9 (1), 112.
18 MacDonald, K.G., Hoeppli, R.E., Huang, Q. et al. (2016) Alloantigen-specific
regulatory T cells generated with a chimeric antigen receptor. J. Clin. Invest.,
126 (4), 1413–1424.
19 Czaja, A.J. (2015) Adoptive cell transfer in autoimmune hepatitis. Expert Rev.
Gastroenterol. Hepatol., 9 (6), 1–16.
20 Chodon, T., Comin-Anduix, B., Chmielowski, B. et al. (2014) Adoptive transfer
of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell
vaccination in patients with metastatic melanoma. Clin. Cancer Res., 20 (9),
2457–2465.
21 Yang, L., Yang, H., Rideout, K. et al. (2008) Engineered lentivector targeting of
dendritic cells for in vivo immunization. Nat. Biotechnol., 26 (3), 326–334.
22 Guillerey, C., Huntington, N.D., and Smyth, M.J. (2016) Targeting natural killer
cells in cancer immunotherapy. Nat. Immunol., 17 (9), 1025–1036.
23 Rezvani, K. and Rouce, R.H. (2015) The application of natural killer cell
immunotherapy for the treatment of cancer. Front. Immunol., 6 , 578.
24 Lu, Y.-C., Yao, X., Crystal, J.S. et al. (2014) Efficient identification of mutated
cancer antigens recognized by T cells associated with durable tumor regressions.
Clin. Cancer Res., 20 (13), 3401–3410.
25 Robbins, P.F., Lu, Y.-C., El-Gamil, M. et al. (2013) Mining exomic sequencing
data to identify mutated antigens recognized by adoptively transferred tumor-
reactive T cells. Nat. Med., 19 (6), 747–752.
26 Kochenderfer, J.N., Dudley, M.E., Kassim, S.H. et al. (2015) Chemotherapy-
refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can
be effectively treated with autologous T cells expressing an anti-CD19 chimeric
antigen receptor. J. Clin. Oncol., 33 , 540–549.
27 Davila, M.L., Riviere, I., Wang, X. et al. (2014) Efficacy and toxicity management
of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl.
Med., 6 (224), 224ra225.
28 Maude, S.L., Frey, N., Shaw, P.A. et al. (2014) Chimeric antigen receptor
T cells for sustained remissions in leukemia. N. Engl. J. Med., 371 (16),
1507–1517.
29 Wang, X., Popplewell, L.L., Wagner, J.R. et al. (2016) Phase 1 studies of central
memory–derived CD19 CAR T–cell therapy following autologous HSCT in
patients with B-cell NHL. Blood, 127 (24), 2980–2990.